EUVIMEDEUVIMED entdecken
Open Access

AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

Estefanía Cerro-Herreros iD, Judit Núñez-Manchón, Neia Naldaiz-Gastesi iD, Marc Carrascosa-Sàez iD, Andrea García-Rey, Diego Piqueras Losilla iD, Irene González-Martínez iD, Jorge Espinosa-Espinosa iD, Kevin Moreno, Javier Poyatos-García iD, Juan J Vilchez iD, Adolfo López de Munain und 4 weitere

Science Advances · 11.10.2024 · 10 (41)

DOI: 10.1126/sciadv.adn6525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 11.10.2024. Verfasst von Estefanía Cerro-Herreros und 15 weiteren Autor:innen. Beteiligte Einrichtung: Human Translational Genomics Group. University Research Institute for Biotechnology and Biomedicine (BIOTECMED), Universidad de Valencia, 46100 Burja…. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Trinucleotide Repeat Expansion, MicroRNAs, RNA-Binding Proteins. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated therapeutic antimiRs in primary myoblasts from patients with myotonic dystrophy type 1 (DM1). DM1 results from unstable CTG repeat expansions in the DMPK gene, leading to variable clinical manifestations by depleting muscleblind-like splicing regulator protein MBNL1. AntimiRs targeting natural repressors miR-23b and miR-218 boost MBNL1 expression but must be optimized for a better pharmacological profile in humans. In untreated cells, miR-23b and miR-218 were up-regulated, which correlated with CTG repeat size, supporting that active MBNL1 protein repression synergizes with the sequestration by CUG expansions in DMPK . AntimiR treatment improved RNA toxicity readouts and corrected regulated exon inclusions and myoblast defects such as fusion index and myotube area across CTG expansions. Unexpectedly, the treatment also reduced DMPK transcripts and ribonuclear foci. A leading antimiR reversed 68% of dysregulated genes. This study highlights the potential of antimiRs to treat various DM1 forms across a range of repeat sizes and genetic backgrounds by mitigating MBNL1 sequestration and enhancing protein synthesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyTrinucleotide Repeat ExpansionMicroRNAsRNA-Binding ProteinsMyotonin-Protein KinaseMyoblastsHumansGene Expression RegulationAntagomirsCells, Cultured

Substanzen

MicroRNAsRNA-Binding ProteinsMBNL1 protein, humanMyotonin-Protein KinaseDMPK protein, humanMIRN23a microRNA, humanAntagomirs

Autor:innen und Institutionen

  • Human Translational Genomics Group. University Research Institute for Biotechnology and Biomedicine (BIOTECMED), Universidad de Valencia, 46100 Burjassot, Valencia, Spain.
  • INCLIVA Biomedical Research Institute, Avenue Menéndez Pelayo 4 acc, 46010 Valencia, Spain.
  • ARTHEx Biotech, Parque Científico de la Universidad de Valencia. Calle del Catedrático Agustín Escardino Benlloch, 9, 46980 Paterna, Valencia, Spain.
  • Group of REsearch Neuromuscular of BAdalona (GRENBA), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Campus Can Ruti, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.
  • Neuromuscular Diseases Group, Neurosciences Area, Biodonostia Health Research Institute, 20014 Donostia/San Sebastián, Spain.
  • CIBERNED, Carlos III Institute, Spanish Ministry of Science and Innovation, Madrid, Spain.

ORCID-Profile: Estefanía Cerro-Herreros, Neia Naldaiz-Gastesi, Marc Carrascosa-Sàez, Diego Piqueras Losilla, Irene González-Martínez, Jorge Espinosa-Espinosa, Javier Poyatos-García, Juan J Vilchez, Mònica Suelves, Gisela Nogales-Gadea, Rubén Artero

Zitieren

APA

Cerro-Herreros, E., Núñez-Manchón, J., Naldaiz-Gastesi, N., Carrascosa-Sàez, M., García-Rey, A., Losilla, D. P., González-Martínez, I., Espinosa-Espinosa, J., Moreno, K., Poyatos-García, J., Vilchez, J. J., de Munain, A. L., Suelves, M., Nogales-Gadea, G., Llamusí, B., & Artero, R. (2024). AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action. Science Advances, 10(41). https://doi.org/10.1126/sciadv.adn6525

Vancouver

Cerro-Herreros E, Núñez-Manchón J, Naldaiz-Gastesi N, Carrascosa-Sàez M, García-Rey A, Losilla DP, et al. AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action. Science Advances. 2024;10(41). doi:10.1126/sciadv.adn6525

BibTeX
@article{CerroHerreros2024,
  author = {Cerro-Herreros, Estefanía and Núñez-Manchón, Judit and Naldaiz-Gastesi, Neia and Carrascosa-Sàez, Marc and García-Rey, Andrea and Losilla, Diego Piqueras and González-Martínez, Irene and Espinosa-Espinosa, Jorge and Moreno, Kevin and Poyatos-García, Javier and Vilchez, Juan J and de Munain, Adolfo López and Suelves, Mònica and Nogales-Gadea, Gisela and Llamusí, Beatriz and Artero, Rubén},
  title = {AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {41},
  doi = {10.1126/sciadv.adn6525}
}
Kostenlos starten →